drugset
drugset / Trial / NCT04005807

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

NCT04005807 ↗

Phase 1 Completed 40 enrolled Belite Bio, Inc
RandomizedSequentialDouble-blindBasic science

Summary

This is single center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of BPN-14967 in healthy adult subjects.

Timeline

Start
2019-07-19
Primary completion
2019-12-20
Completion
2019-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Tinlarebant Small molecule 10 mg Oral
Subject Tinlarebant Small molecule 25 mg Oral
Subject Tinlarebant Small molecule 50 mg Oral

Indications

No indication recorded.